


Practitioner's Docket No: 700157-47577C

PATENT



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of: Marasco et al.

Application No.: 09/522,727

Group No.: 1644

Filed: 3/10/00

Examiner: J. Roark

RECEIVED

JUL 11 2002

TECH CENTER 1600/2900

For: INTRABODY-MEDIATED CONTROL OF IMMUNE REACTIONS

Assistant Commissioner for Patents
Washington, D.C. 20231

SUBMISSION OF "SEQUENCE LISTING," COMPUTER READABLE COPY,
AND/OR AMENDMENT PERTAINING THERETO
FOR BIOTECHNOLOGY INVENTION CONTAINING NUCLEOTIDE
AND/OR AMINO ACID SEQUENCE

IDENTIFICATION OF PERSON MAKING STATEMENT

2. I, Ronald I. Eisenstein, state the following:

ITEMS BEING SUBMITTED

3. Submitted herewith is/are:

A copy of each "Sequence Listing" submitted for this application in computer readable form, in accordance with the requirements of 37 C.F.R. §§ 1.821(e) and 1.824.

CERTIFICATION UNDER 37 C.F.R. 1.8(a) and 1.10*

(When using Express Mail, the Express Mail label number is mandatory;
Express Mail certification is optional.)

I hereby certify that, on the date shown below, this correspondence is being:

MAILING


☒ deposited with the United States Postal Service in an envelope addressed to the Assistant Commissioner for Patents, Washington, D.C. 20231.

37 C.F.R. 1.8(a)

37 C.F.R. 1.10*

☒ with sufficient postage as first class mail.

☐ as "Express Mail Post Office to Address"
Mailing Label No. _____ (mandatory)


(Signature)

Zinna L. Mang
(type or print name of person certifying)

Date: 7/3/02

A statement that the content of each "Sequence Listing" submitted and each computer readable copy are the same, as required in 37 C.F.R. § 1.821(g).

An Amendment Under 37 C.F.R. § 1.825.

Because this submission is made in fulfilling the requirement under 37 C.F.R. § 1.821(g), a statement that the submission includes no new matter.

**STATEMENT THAT "SEQUENCE LISTING"
AND COMPUTER READABLE COPY ARE THE SAME
AND/OR THAT PAPERS SUBMITTED INCLUDES NO NEW MATTER**

4. I hereby state:

All papers accompanying this submission, or for which a request for transfer from applicants' other application, introduce no new matter.

The "Sequence Listing" and computer readable copy are the same.

If any additional extension and/or fee is required, charge Account No. 50-0850.


SIGNATURE OF PRACTITIONER


Reg. No. 30,628

Ronald I. Eisenstein


Tel. No.: (617) 345-6054

NIXON PEABODY LLP
101 Federal Street

Boston, MA 02110



RECEIVED
JUL 11 2002
TECH CENTER 1600/2900



1644

RAW SEQUENCE LISTING

PATENT APPLICATION: US/09/522,727C

DATE: 02/21/2002

TIME: 11:13:55

Input Set : A:\#538999 v1 - seqlist.txt

Output Set: N:\CRF3\02212002\I522727C.raw

Does Not Comply
Corrected Diskette Needed

pp 1-2

4 <110> APPLICANT: DANA-FARBER CANCER INSTITUTE, INC.
5 MARASCO, Wayne
6 MHASHILKAR, Abner
8 <120> TITLE OF INVENTION: INTRABODY-MEDIATED CONTROL OF IMMUNE REACTIONS
10 <130> FILE REFERENCE: 47577 C
12 <140> CURRENT APPLICATION NUMBER: US/09/522,727C
13 <141> CURRENT FILING DATE: 2000-03-10
15 <150> PRIOR APPLICATION NUMBER: 60/059,339
16 <151> PRIOR FILING DATE: 1997-09-19
18 <160> NUMBER OF SEQ ID NOS: 56
20 <170> SOFTWARE: FastSEQ for Windows Version 3.0

ERRORED SEQUENCES

22 <210> SEQ ID NO: 1
23 <211> LENGTH: 5 *15 shown*
24 <212> TYPE: PRT
25 <213> ORGANISM: human
27 <400> SEQUENCE: 1
28 Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser
E--> 29 1 5 10 15
690 <210> SEQ ID NO: 54
691 <211> LENGTH: 277
692 <212> TYPE: PRT
693 <213> ORGANISM: human
695 <400> SEQUENCE: 54
696 Met Glu His Leu Trp Phe Phe Leu Leu Leu Val Ala Ala Pro Arg Trp
697 1 5 10 15
698 Val Leu Ser Gln Val Gln Leu Gln Gln Ser Gly Ala Glu Leu Thr Arg
699 20 25 30
700 Pro Gly Ala Ser Val Lys Leu Ser Cys Lys Ala Ser Gly Tyr Thr Phe
701 35 40 45
702 Thr Ser His Trp Met Gln Trp Val Arg Gln Arg Pro Gly Gln Gly Leu
703 50 55 60
704 Glu Trp Ile Gly Thr Ile Tyr Pro Gly Asp Gly Asp Thr Arg Tyr Thr
705 65 70 75 80
706 Gln Asn Phe Lys Gly Lys Ala Thr Leu Thr Ala Asp Lys Ser Ser Thr
707 85 90 95
708 Thr Ala Tyr Leu His Leu Ser Ser Leu Ser Ser Glu Asp Ser Ala Val
E--> 709 100 105 *110 ← insert*
710 Tyr Tyr Cys Ala Arg Asp Glu Ile Thr Thr Val Val Pro Arg Gly Phe
711 115 120 125

RAW SEQUENCE LISTING

PATENT APPLICATION: US/09/522,727C

DATE: 02/21/2002

TIME: 11:13:55

Input Set : A:\#538999 v1 - seqlist.txt

Output Set: N:\CRF3\02212002\I522727C.raw

712	Ala	Tyr	Trp	Gly	Gln	Gly	Thr	Leu	Val	Thr	Val	Ser	Ser	Gly	Gly	Gly
713		130					135					140				
714	Gly	Ser	Gly	Gly	Gly	Gly	Ser	Gly	Gly	Gly	Gly	Ser	Glu	Leu	Val	Leu
715	145					150					155					160
716	Thr	Gln	Ser	Pro	Ser	Ser	Leu	Ser	Ala	Ser	Leu	Gly	Asp	Thr	Ile	Thr
717					165					170						175
718	Ile	Thr	Cys	His	Ala	Ser	Gln	Asn	Ile	Asn	Val	Trp	Leu	Ser	Trp	Tyr
719				180					185					190		
720	Gln	Gln	Lys	Pro	Gly	Asn	Ile	Pro	Gln	Leu	Leu	Ile	Tyr	Lys	Ala	Ser
721			195					200					205			
722	Asn	Leu	His	Thr	Gly	Val	Pro	Ser	Arg	Phe	Ser	Gly	Arg	Gly	Ser	Gly
723		210					215					220				
724	Thr	Gly	Phe	Thr	Leu	Thr	Ile	Ser	Ser	Leu	Gln	Pro	Glu	Asp	Ile	Gly
725	225					230					235					240
726	Thr	Tyr	Tyr	Cys	Gln	Gln	Gly	Gln	Ser	Tyr	Pro	Leu	Thr	Phe	Gly	Gly
727				245					250						255	
728	Gly	Thr	Lys	Leu	Glu	Ile	Lys	Arg	Ala	Asp	Ala	Ala	Pro	Thr	Val	Ser
729				260					265						270	
730	Glu	Lys	Asp	Glu	Leu											

Use of n or Xaa has been detected in the Sequence Listing.
Review the Sequence Listing to insure a corresponding
explanation is presented in the <220> to <223> fields of
each sequence using n or Xaa.

VERIFICATION SUMMARY

PATENT APPLICATION: US/09/522,727C

DATE: 02/21/2002

TIME: 11:13:56

Input Set : A:\#538999 v1 - seqlist.txt

Output Set: N:\CRF3\02212002\I522727C.raw

L:12 M:270 C: Current Application Number differs, Replaced Current Application Number
 L:13 M:271 C: Current Filing Date differs, Replaced Current Filing Date
 L:29 M:252 E: No. of Seq. differs, <211>LENGTH:Input:5 Found:15 SEQ:1
 L:284 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:29
 L:286 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:29
 L:526 M:258 W: Mandatory Feature missing, <223> not found for SEQ ID#:51
 L:526 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:51
 L:527 M:258 W: Mandatory Feature missing, <223> not found for SEQ ID#:51
 L:527 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:51
 L:590 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:52
 L:709 M:332 E: (32) Invalid/Missing Amino Acid Numbering, SEQ ID:54